Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 hours
DelveInsight’s, “Antisense Oligonucleotide Therapeutics – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Antisense Oligonucleotide Therapeutics: Overview
Antisense oligonucleotides (ASOs) are short, synthetic, single-stranded oligodeoxynucleotides that can alter RNA and reduce, restore, or modify protein expression through several distinct mechanisms. By targeting the source of the pathogenesis, ASO-mediated therapies have an higher chance of success than therapies targeting downstream pathways. Advances in the understanding of ASO pharmacology have provided momentum for translating these therapeutics into the clinic. Two ASO-mediated therapies have received approval from the US Food and Drug Administration for the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. Further advancement of ASOs in the clinic urgently requires optimization of ASO delivery, target engagement, and safety profile.
'Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Antisense Oligonucleotide Therapeutics pipeline landscape is provided which includes the disease overview and Antisense Oligonucleotide Therapeutics treatment guidelines. The assessment part of the report embraces, in depth Antisense Oligonucleotide Therapeutics commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Antisense Oligonucleotide Therapeutics collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Antisense Oligonucleotide Therapeutics report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Antisense Oligonucleotide Therapeutics Emerging Drugs
Further product details are provided in the report……..
Antisense Oligonucleotide Therapeutics: Therapeutic Assessment
This segment of the report provides insights about the different Antisense Oligonucleotide Therapeutics drugs segregated based on following parameters that define the scope of the report, such as:
Antisense Oligonucleotide Therapeutics: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Antisense Oligonucleotide Therapeutics therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Antisense Oligonucleotide Therapeutics drugs.
Antisense Oligonucleotide Therapeutics Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Antisense Oligonucleotide Therapeutics – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Antisense Oligonucleotide Therapeutics: Overview
Antisense oligonucleotides (ASOs) are short, synthetic, single-stranded oligodeoxynucleotides that can alter RNA and reduce, restore, or modify protein expression through several distinct mechanisms. By targeting the source of the pathogenesis, ASO-mediated therapies have an higher chance of success than therapies targeting downstream pathways. Advances in the understanding of ASO pharmacology have provided momentum for translating these therapeutics into the clinic. Two ASO-mediated therapies have received approval from the US Food and Drug Administration for the treatment of Duchenne muscular dystrophy and spinal muscular atrophy. Further advancement of ASOs in the clinic urgently requires optimization of ASO delivery, target engagement, and safety profile.
'Antisense Oligonucleotide Therapeutics - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Antisense Oligonucleotide Therapeutics pipeline landscape is provided which includes the disease overview and Antisense Oligonucleotide Therapeutics treatment guidelines. The assessment part of the report embraces, in depth Antisense Oligonucleotide Therapeutics commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Antisense Oligonucleotide Therapeutics collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Antisense Oligonucleotide Therapeutics R&D. The therapies under development are focused on novel approaches to treat/improve Antisense Oligonucleotide Therapeutics.
This segment of the Antisense Oligonucleotide Therapeutics report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Antisense Oligonucleotide Therapeutics Emerging Drugs
- Cobitolimod: InDex Pharmaceuticals
- Prexigebersen: Bio-Path Holdings
Further product details are provided in the report……..
Antisense Oligonucleotide Therapeutics: Therapeutic Assessment
This segment of the report provides insights about the different Antisense Oligonucleotide Therapeutics drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Antisense Oligonucleotide Therapeutics
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Antisense Oligonucleotide Therapeutics: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Antisense Oligonucleotide Therapeutics therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Antisense Oligonucleotide Therapeutics drugs.
Antisense Oligonucleotide Therapeutics Report Insights
- Antisense Oligonucleotide Therapeutics Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Antisense Oligonucleotide Therapeutics drugs?
- How many Antisense Oligonucleotide Therapeutics drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Antisense Oligonucleotide Therapeutics?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Antisense Oligonucleotide Therapeutics therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Antisense Oligonucleotide Therapeutics and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Antisense Oligonucleotide Therapeutics: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Cobitolimod: InDex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Prexigebersen: Bio-Path Holdings
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
ALG-020572: Aligos Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Antisense Oligonucleotide Therapeutics Key Companies
Antisense Oligonucleotide Therapeutics Key Products
Antisense Oligonucleotide Therapeutics- Unmet Needs
Antisense Oligonucleotide Therapeutics- Market Drivers and Barriers
Antisense Oligonucleotide Therapeutics- Future Perspectives and Conclusion
Antisense Oligonucleotide Therapeutics Analyst Views
Antisense Oligonucleotide Therapeutics Key Companies
Appendix
Executive Summary
Antisense Oligonucleotide Therapeutics: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Cobitolimod: InDex Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
Prexigebersen: Bio-Path Holdings
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
ALG-020572: Aligos Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Antisense Oligonucleotide Therapeutics Key Companies
Antisense Oligonucleotide Therapeutics Key Products
Antisense Oligonucleotide Therapeutics- Unmet Needs
Antisense Oligonucleotide Therapeutics- Market Drivers and Barriers
Antisense Oligonucleotide Therapeutics- Future Perspectives and Conclusion
Antisense Oligonucleotide Therapeutics Analyst Views
Antisense Oligonucleotide Therapeutics Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Antisense Oligonucleotide Therapeutics
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Antisense Oligonucleotide Therapeutics
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Antisense Oligonucleotide Therapeutics
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Antisense Oligonucleotide Therapeutics
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
